Dr Szczech provides a sobering view on what extreme actions uninsured immigrants are taking to push their symptom boundaries to near death every week in order to get emergent hemodialysis.

Dr Gregg Stone reviews the questions to ask before accepting the results of a 'positive' clinical trial.

We need large-scale observational studies of real-world patients to determine the safety and efficacy of lower doses of NOACs, says Dr Goldhaber.

The positive effects of empagliflozin on renal disease are discussed by Dr Christoph Wanner, one of the lead authors of the EMPA-REG OUTCOME trial.

According to Dr Tasian, the incidence of kidney stone disease in children is growing. Yet, uncertainties in diagnosis and management persist.

Screening everyone for chronic kidney disease is neither cost-efficient nor useful, says Dr Berns.

Drs Steve Edelman and Jeremy Pettus interview 'bionic pancreas' developer Ed Damiano to get the latest information on the much-awaited device.

Eight million Americans have diabetes and don't know it. How can we persuade the public, the government, and the scientific community to focus on this invisible epidemic?

With empagliflozin, pioglitazone, and liraglutide, we may finally be getting closer to the 'holy grail' of a diabetes drug that also has cardiovascular benefits.

Dr Thomas Allison sits down with Dr Francisco Lopez-Jimenez and Dr Steven Kopecky to talk about the use of LDL-C goals, and their approach to cholesterol management following the IMPROVE-IT trial.